Related Experiment Video

Updated: Jun 2, 2026

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma
06:11

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Published on: April 20, 2018

RECQL1 and WRN proteins are potential therapeutic targets in head and neck squamous cell carcinoma

Akihito Arai1, Tokuhiro Chano, Kazunobu Futami

  • 1Department of Clinical Laboratory Medicine, Shiga University of Medical Science, Shiga, Japan.

Cancer Research
|May 17, 2011
PubMed

Insights

Targeting RECQL1 and WRN DNA helicases shows promise for treating aggressive hypopharyngeal carcinomas. Silencing these proteins inhibited cancer growth and enhanced chemotherapy effectiveness in preclinical models.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • RecQ DNA helicases, RECQL1 and WRN, are crucial for DNA repair and suppressing genomic instability.
  • Hypopharyngeal carcinoma, a subset of head and neck squamous cell carcinoma (HNSCC), has a poor prognosis and increasing incidence.
  • Identifying novel therapeutic targets for aggressive HNSCC is a critical unmet need.

Purpose of the Study:

  • To investigate the potential of RECQL1 and WRN as therapeutic targets for hypopharyngeal carcinoma.
  • To evaluate the efficacy of targeting RECQL1 and WRN in preclinical models of HNSCC.

Main Methods:

  • Analysis of RECQL1 and WRN protein expression in hypopharyngeal carcinoma tissues.
  • In vitro studies using siRNA-mediated gene silencing to assess effects on carcinoma cell growth.
  • In vivo studies using a murine xenograft model of hypopharyngeal carcinoma, including combination therapy with cisplatin.

Main Results:

  • RECQL1 and WRN proteins were found to be highly expressed in hypopharyngeal carcinomas.
  • siRNA-mediated silencing of RECQL1 or WRN significantly suppressed carcinoma cell growth in vitro.
  • Tumor growth was markedly inhibited in vivo following siRNA administration, with enhanced effects when combined with cisplatin.

Conclusions:

  • RECQL1 and WRN are potential novel therapeutic targets for aggressive HNSCC.
  • Targeting RECQL1 and WRN, particularly in combination with chemotherapy, demonstrates preclinical efficacy.
  • Further investigation into RECQL1 and WRN as cancer therapeutic targets is warranted.

More Related Videos

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

Translationally-Relevant Tumor Resection Model for Murine Preclinical Models of Oral Squamous Cell Carcinoma07:59

Translationally-Relevant Tumor Resection Model for Murine Preclinical Models of Oral Squamous Cell Carcinoma

Published on: April 3, 2026

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes: